Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C19-A3 proinsulin peptide coupled to gold nanoparticles
- Development stage
- Unknown
- Lead developer
- Biodexa Pharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides
- Administration
- Intradermal
01
Overview
C19-A3 proinsulin peptide coupled to gold nanoparticles (Midacore) is an investigational antigen-specific immunotherapy designed for the treatment of type 1 diabetes mellitus. Developed by Cardiff University in collaboration with Midatech Pharma (now Biodexa Pharmaceuticals), the therapeutic consists of an 18-amino acid human proinsulin peptide (C19-A3) spanning residues from position 19 of the C-peptide to position 3 of the A-chain. This peptide is covalently coupled via a thiol linker to ultrasmall gold nanoparticles (GNPs) of less than 5 nm in size. The drug is administered intradermally using a microneedle delivery system (MicronJet600) to target skin-resident antigen-presenting cells, particularly Langerhans cells. These cells process and present the proinsulin autoantigen to HLA-DR4-restricted T cells, aiming to induce immune tolerance and halt the autoimmune destruction of pancreatic beta-cells. Gold nanoparticles serve as a delivery platform to enhance peptide uptake and potentially provide anti-inflammatory properties.
- Brand names
- Midacore
- Other names
- C19-A3-GNPC-19-A3-GNPC 19-A3-GNPproinsulin peptide C19-A3 gold nanoparticle conjugate
02
Targets
HLA-DRB1*04:01 (HLA class II histocompatibility antigen DRB1*04:01)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on C19-A3 proinsulin peptide coupled to gold nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C19-A3 proinsulin peptide coupled to gold nanoparticles.